Who Owns enGene Therapeutics Stock?
NASDAQ: ENGNHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 84.11%
- Held by insiders
- 0.11%
- Institutional holders
- 66
- Institutions 84.1%
- Insiders 0.1%
- Public and other 15.8%
Who owns enGene Therapeutics stock?
Institutional investors own about 84.1% of enGene Therapeutics's shares, spread across 66 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 0.11% of ENGN.
The largest institutional holders are FCPM III Services B.V. (14.37%), BML Capital Management, LLC (9.95%) and Siren, L.L.C. (9.34%). Together, the top 10 institutions control 57.5% of shares outstanding. In their latest filings, 6 of the top 10 institutions increased their ENGN positions and 2 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of ENGN
| Institution | Shares | % Held | Change |
|---|---|---|---|
| FCPM III Services B.V. | 9.63M | 14.37% | 0.0% |
| BML Capital Management, LLC | 6.67M | 9.95% | +100.0% |
| Siren, L.L.C. | 6.26M | 9.34% | +19.1% |
| Perceptive Advisors Llc | 4.82M | 7.20% | -17.3% |
| Ameriprise Financial, Inc. | 2.68M | 3.99% | +100.0% |
| Nextech Invest, Ltd. | 2.32M | 3.47% | 0.0% |
| Adar1 Capital Management, LLC | 2.10M | 3.14% | +1474.6% |
| Vestal Point Capital, LP | 1.67M | 2.49% | -23.0% |
| Acorn Capital Advisors, LLC | 1.27M | 1.90% | +100.0% |
| Peapod Lane Capital LLC | 1.10M | 1.64% | +100.0% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of ENGN
| Fund | Shares | % Held |
|---|---|---|
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 34.98K | 0.05% |
| TIFF INVESTMENT PROGRAM-TIFF Multi-Asset Fund | 10.64K | 0.02% |
| JNL Series Trust-JNL/DFA U.S. Small Cap Fund | 9.97K | 0.01% |
| Exchange Place Advisors Trust-North Square Kennedy MicroCap Fund | 7.65K | 0.01% |
| Advanced Series Trust-AST SMALL-CAP EQUITY PORTFOLIO | 1.38K | 0.00% |
Frequently asked questions
Who is the largest shareholder of enGene Therapeutics?
FCPM III Services B.V. is the largest institutional shareholder of ENGN, owning 14.37% of shares outstanding (9.63M shares) as of its latest 13F filing.
What percentage of enGene Therapeutics is owned by institutions?
Institutions own about 84.1% of ENGN shares and 84.2% of the public float.
How much of enGene Therapeutics do insiders own?
Insiders, such as officers and directors, own about 0.11% of ENGN shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.